

Hardcore-Notfallpharmakologie: Gerinnungshemmung nach STEMI

Autor:

**Matthias
Bastigkeit**
Fachdozent für
Pharmakologie,
Dorfstraße 83,
23815
Geschendorf,
Bastigkeit@
aol.com

Literatur:

1. Cannon CP, Harrington RA, James S et al. (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. *Lancet* 375: 283-293
2. Christ G (2009) Prasugrel – Klinischer Stellenwert nach TRITON-TIMI 38. *Journal für Kardiologie – Austrian, Journal of Cardiology* 16 (11-12): 453-455
3. CIPAMI-Study (2011) Clopidogrel Administered Pre-hospital to Improve Primary PCI in Patients With Acute Myocardial Infarction. <http://clinicaltrials.gov/ct2/show/NCT00372216>
4. Connolly SJ et al. for the RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*, Aug 30
5. Diener HC et al. (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial. *Lancet Neurol* Dec 9: 1157
6. ESC/EACTS GUIDELINES (2010) Guidelines on myocardial revascularization. *European Heart Journal* 31: 2501-2555
7. Mahaffey KW, Wojdyla DM, Carroll K et al. (2011) Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. *Circulation* DOI: 10.1161/CIR.0b013e318226950d..
8. Montalescot G et al. (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. *Lancet* 373: 723-31
9. Ohman EM, Roe MT (2011) Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. *Thromb Haemost* DOI: 10.1160/TH11-03-0159.
10. Price MJ, Berger PB, Teirstein PS et al. (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 305: 1097-1105
11. Schirmer SH, Böhm M (2011) Aktuelles zur Thrombozytenaggregationshemmung. *Dtsch med Wochenschr* 136 (23): 1260-1264
12. Serebruany VL (2011) Paradoxical excess mortality in the PLATO trial should be independently verified. *Thromb Haemost* DOI:10.1160/TH10-12-0807..
13. Serebruany VL (2011) Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. *Thromb Haemost* 105: 752-759
14. Wallentin L, Becker RC, James S et al. (2011) The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. *Thromb Haemost* DOI: 10.1160/TH11-03-0162.
15. Wallentin L et al. (2009) Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. *NEJM* doi: 10.1056/NEJMoa0904327
16. Wiviott SD et al. (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. *Lancet* 371: 1353-63